RNAC Quote, Financials, Valuation and Earnings

Cabaletta Bio, Inc. has a net margin of -7942.92% compared to Cartesian Therapeutics, Inc.'s net margin of --. Cartesian Therapeutics, Inc.'s return on equity of -- beat Cabaletta Bio, Inc.'s return on equity of -103.46%.

Cartesian Therapeutics, Inc. has a consensus price target of $35.29, signalling upside risk potential of 430.61%. On the other hand Cabaletta Bio, Inc. has an analysts' consensus of $14.13 which suggests that it could grow by 451.76%. Given that Cabaletta Bio, Inc. has higher upside potential than Cartesian Therapeutics, Inc., analysts believe Cabaletta Bio, Inc. is more attractive than Cartesian Therapeutics, Inc..

Cartesian Therapeutics, Inc. has a beta of 0.506, which suggesting that the stock is 49.39% less volatile than S&P 500. In comparison Cabaletta Bio, Inc. has a beta of 3.171, suggesting its more volatile than the S&P 500 by 217.108%.

Cartesian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cabaletta Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cartesian Therapeutics, Inc. pays -- of its earnings as a dividend. Cabaletta Bio, Inc. pays out -- of its earnings as a dividend.

Cartesian Therapeutics, Inc. quarterly revenues are $452K, which are larger than Cabaletta Bio, Inc. quarterly revenues of --. Cartesian Therapeutics, Inc.'s net income of -$35.9M is higher than Cabaletta Bio, Inc.'s net income of -$44.9M. Notably, Cartesian Therapeutics, Inc.'s price-to-earnings ratio is -- while Cabaletta Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cartesian Therapeutics, Inc. is 74.19x versus -- for Cabaletta Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -7942.92% compared to Cartesian Therapeutics, Inc.'s net margin of -255.85%. Cartesian Therapeutics, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Cartesian Therapeutics, Inc. has a consensus price target of $35.29, signalling upside risk potential of 430.61%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that Cartesian Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Cartesian Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Cartesian Therapeutics, Inc. has a beta of 0.506, which suggesting that the stock is 49.39% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Cartesian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Cartesian Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Cartesian Therapeutics, Inc. quarterly revenues are $452K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Cartesian Therapeutics, Inc.'s net income of -$35.9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Cartesian Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cartesian Therapeutics, Inc. is 74.19x versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -7942.92% compared to Cartesian Therapeutics, Inc.'s net margin of --. Cartesian Therapeutics, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.

Cartesian Therapeutics, Inc. has a consensus price target of $35.29, signalling upside risk potential of 430.61%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Cartesian Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Cartesian Therapeutics, Inc..

Cartesian Therapeutics, Inc. has a beta of 0.506, which suggesting that the stock is 49.39% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Cartesian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cartesian Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Cartesian Therapeutics, Inc. quarterly revenues are $452K, which are larger than Palatin Technologies quarterly revenues of --. Cartesian Therapeutics, Inc.'s net income of -$35.9M is higher than Palatin Technologies's net income of --. Notably, Cartesian Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cartesian Therapeutics, Inc. is 74.19x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -7942.92% compared to Cartesian Therapeutics, Inc.'s net margin of --. Cartesian Therapeutics, Inc.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Cartesian Therapeutics, Inc. has a consensus price target of $35.29, signalling upside risk potential of 430.61%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3398.25%. Given that Theriva Biologics, Inc. has higher upside potential than Cartesian Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Cartesian Therapeutics, Inc..

Cartesian Therapeutics, Inc. has a beta of 0.506, which suggesting that the stock is 49.39% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Cartesian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cartesian Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Cartesian Therapeutics, Inc. quarterly revenues are $452K, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Cartesian Therapeutics, Inc.'s net income of -$35.9M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Cartesian Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cartesian Therapeutics, Inc. is 74.19x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.